INDIGO is the largest clinical trial conducted in patients living with IgG4-RD--Topline INDIGO results expected by the end of 2025-WALTHAM, ...
Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback